TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01206725

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
Study: NCT01094119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heated blanket
Description: heated blanket
Study: NCT01130974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb contact lens
Description: Bausch \& Lomb daily disposable cosmetic tint contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed daily disposable contact lens
Description: Marketed daily disposable cosmetic tint contact lens
Study: NCT02929745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Four 4-5 mm punch biopsies of the skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Four 4-5 mm punch biopsies of the skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Four 4-5 mm punch biopsies of the skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to test for HLA-cw6 status

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to test for HLA-cw6 status

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to test for HLA-cw6 status
Study: NCT01143103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough assist (Philips,respironics)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual respiratory therapy
Study: NCT03782142

Intervention type: DRUG
Intervention: Tenofovir
Description: TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)

Intervention type: DRUG
Intervention: Tenofovir
Description: TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)

Intervention type: DRUG
Intervention: Tenofovir
Description: TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)

Intervention type: DRUG
Intervention: Rilpivirine
Description: NNRTI

Intervention type: DRUG
Intervention: Prezcobix
Description: PI

Intervention type: DRUG
Intervention: Dolutegravir
Description: II
Study: NCT00768391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-3G3
Description: Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
Study: NCT00569816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
Study: NCT01615653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: EUS Guided Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: EUS Guided Therapy
Study: NCT00651157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: wild-type reovirus
Description: Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
Study: NCT01721603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg capsule by mouth twice daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery
Description: This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
Study: NCT00916630

Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed
Description: Given intravenously over a 10 to 20 minute period once every 14 days.
Study: NCT04379648

Intervention type: OTHER
Group type: OTHER
Intervention: self-assessment and hetero-assessment
Description: Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
Study: NCT04047654

Intervention type: DRUG
Intervention: Non vitamin K oral anticoagulants
Description: Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
Study: NCT02472080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine -oxaliplatine combination
Description: gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
Study: NCT00248846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study: NCT03620019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
Study: NCT02884765

Intervention type: PROCEDURE
Intervention: Non-surgical
Description: Non-surgical treatment in both condylar fractures

Intervention type: PROCEDURE
Intervention: Non-surgical / Surgical
Description: Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture

Intervention type: PROCEDURE
Intervention: Surgical
Description: Surgical treatment in both condylar fractures
Study: NCT01174238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
Study: NCT00898443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural anesthetic
Description: Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal anesthetic
Description: This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
Study: NCT04574479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra-inguinal fascia iliaca compartment block
Description: Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia and PCA morphine pump
Description: Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal analgesia and PCA morphine pump
Description: Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
Study: NCT03142971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focused shock wave therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound therapy
Study: NCT01369901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A functional exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A stretching exercise program
Study: NCT03975023

Intervention type: DEVICE
Intervention: NeuroCatch Platform (NCP)
Description: The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
Study: NCT00724295

Intervention type: DRUG
Intervention: peginterferon alfa-2b
Description: PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.

Intervention type: DRUG
Intervention: ribavirin
Description: Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
Study: NCT01868451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Site Radiation Therapy (ISRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Site Radiation Therapy (ISRT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interim PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interim PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interim PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interim PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: consolidation volume RT (CVRT)
Study: NCT05138913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA
Description: After the arthroscopic operation was completed, a local TXA injection was performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the arthroscopic operation was completed, a local saline injection was performed
Study: NCT03706950

Intervention type: DRUG
Intervention: Elpida® + 2 NRTIs
Description: Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
Study: NCT01050205

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Intervention
Description: Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings.
Study: NCT01238289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education
Description: Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group continues with standard care at the community health center
Study: NCT04097522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback
Description: During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
Study: NCT00324701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychology
Description: therapy done at patients house

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face therapy
Description: therapy delivered at the VAMC
Study: NCT01561222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 ug per day for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one pill per day
Study: NCT03093779

Intervention type: OTHER
Intervention: Health Information Assessment
Description: Assess how hearing loss and health literacy alters the ability to access and comprehend online health information

Intervention type: OTHER
Intervention: Health Information Assessment
Description: Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
Study: NCT01119001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P300 Brain Computer Interface Keyboard
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
Study: NCT01891721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program (BFP)
Description: This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Package (Cogpack)
Description: This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Computer Games (Sporcle)
Description: Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours.
Study: NCT02827136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch and hypafix
Description: Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypafix
Description: Appliance of hypafix on both shoulder tip after anesthetic induction
Study: NCT02721823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle-modification
Description: The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.